Evidence map›Paper›PMID 38993360›Full record

ArticleBladder cancer (Amsterdam, Netherlands)2022

Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter.

Ashish M Kamat, Niyati Lobo, Seth P Lerner, Roger Li, Justin T Matulay, Joan Palou, J Alfred Witjes, Morgan Rouprêt, Angela B Smith, Sam S Chang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bladder cancer (Amsterdam, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ashish M KamatDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Niyati LoboDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Seth P LernerScott Department of Urology, Baylor College of Medicine, Houston, TX, USA.
Roger LiDepartment of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Justin T MatulayDepartment of Urology, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.
Joan PalouDepartment of Urology, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain.
J Alfred WitjesDepartment of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.
Morgan RouprêtUrology, GRC n°5, Predictive ONCO-URO, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France.
Angela B SmithDepartment of Urology, University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Sam S ChangDepartment of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.
Neal D ShoreDepartment of Urology, Carolina Urologic Research Center, Myrtle Beach, SC, USA.
Gary D SteinbergDepartment of Urology, NYU Langone Health, New York, NY, USA.
Colin P DinneyDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Robert S SvatekDepartment of Urology, University of Texas Health San Antonio, San Antonio, TX, USA.
Donald L LammDepartment of Surgery, University of Arizona and BCG Oncology, Phoenix, AZ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

When it comes to the treatment of patients with non-muscle-invasive bladder cancer (NMIBC) with intravesical bacillus Calmette-Guérin (BCG), two questions must be considered: 1) what dose to give, and 2) for how long? The issue of optimal dose and duration has been the subject of several randomized trials and is especially pertinent in the context of a global BCG shortage. Despite this, there appears to be uncertainty as to whether BCG dose or duration may be compromised in the event of shortage. As such, we wish to summarize the available evidence as an aid to the practicing urologist.

Indexed as

bacillus Calmette-GuerinimmunotherapyNon-muscle-invasive bladder cancerreduced dose

Identifiers

PMID38993360
PMCPMC11181808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.